Abstract
Today, there are many more dia- betes drugs on the market than there were 10 or 20 years ago. The last five years alone have seen the introduction of new classes of oral antidiabetic drugs (OADs) includ- ing the glitazones and secreta- gogues. In addition, there is a pipeline of drugs in development including a new range of insulins. This, coupled with the escalating numbers of patients suffering from diabetes, means that the manage- ment of diabetes has never been more challenging. All new drugs undergo a com-
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
